
Nanna Lüneborg PhD, MBA
General Partner
NM26 targets IL-4Rα (type I and type II receptors) and IL-31, to address the hallmarks of the pathophysiology of atopic dermatitis. The antibody was discovered and engineered, using Numab’s proprietary MATCH technology platform, which is designed to fuel a new wave of multi-specific antibody drug candidates.
Human Health
CH
Numab Therapeutics AG
Einsiedlerstrasse 34
CH-8820 Wädenswil
Industry
Biotech
Status
Realised